PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Methylphenidate hydrochloride - Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs

PAD Profile : Methylphenidate hydrochloride - Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs

Keywords :
Attention Deficit Hyperactivity Disorder, ADHD,
Brand Names Include :
Concerta XL, Delmosart, Equasym XL, Medikinet XL, Matoride XL, Xenidate XL, Xaggitin XL, Ritalin XL, Metyrol XL, Affenid XL, Meflynate XL, Ritalin , Medikinet, Tranquilyn,

Traffic Light Status

Status 1 of 2.

Status :
Amber
Important
Formulations :
  • Modified release tablets
Important Information :
Prescribe by brand. Xaggitin XL, Xenidate XL and Delomsart are the locally agreed brands.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
CD
Comments :
No comments returned.

Status 2 of 2.

Status :
Amber
Important
Formulations :
  • Immediate release tablets
Important Information :
Prescribe immediate release tablets generically
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
CD
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
03 July 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

MODIFIED RELEASE TABLETS (18, 27, 36 and 54mg):

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed the recommendation to prescribe the branded generic Methylphenidate modified release preparations (18, 27, 36 and 54mg) with the lowest acquisition cost.
Such products have an AMBER traffic light status and are the preferred alternatives to Concerta®.  
- See the "Branded generic methylphenidate letters" for information for patients and clinicians
N.B. This guidance does not apply to other strengths of modified release methylphenidate as these have different release characteristics

12 October 2023
Surrey Heartlands Medicines Safety Committee (MSC)

Information on management of ADHD medication stock shortages

There are currently supply disruptions affecting various medications which are licensed for the treatment of attention deficit hyperactivity disorder (ADHD).

A national patient safety alert has been issued and we have been liaising with colleagues both regionally and nationally about the ongoing situation.  We have been advised that centrally they are looking at publishing further guidance but until this is published we have been working with colleagues from Surrey & Borders Partnership NHS Trust and the Local Pharmaceutical Committee to produce the pack below which provides useful information and clinical recommendations about how to manage these shortages. 

04 October 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Shared Care arrangements for children and adolescents with ADHD are in place with Surrey and Borders Partnership NHS Foundation Trust.

Guildford & Waverley, North West Surrey and Surrey Downs have agreed a Locally Commissioned Service (LCS) for practices entering into the shared care agreement with Surrey & Borders Partnership. The LCS supports the provision of an annual physical medication review by the GP (with an annual review by the specialist so that the patient continues to receive a 6-monthly review in accordance with the product license)
See below for a copy of the Shared care with LCS agreement

There is also a non-LCS shared care agreement that is available for all non-LCS participating practices (see shared care agreement below)

Associated BNF Codes

04. Central Nervous System
04.04.00. CNS stimulants and drugs used for ADHD
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More